8
Oct
2024

Bachem AG

Exhibitor at CPHI Milan 2024 stand 2A26, API
About Us

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CH
  • 2015
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Primary activities
API Producer
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 2A26, API

Products Featured at CPHI Milan 2024

  • Antazoline Hydrochloride

    Product Antazoline Hydrochloride

    Fields of Application: Conjunctivitis.  Antazoline Hydrochloride is an ethylenediamine derivative with antihistaminic properties and is used in conjunction with a vasoconstrictor for ocular allergies.
  • Antazoline Phosphate

    Product Antazoline Phosphate

    Fields of Application: Conjunctivitis. Antazoline Hydrochloride is an ethylenediamine derivative with antihistaminic properties and is used in conjunction with a vasoconstrictor for ocular allergies.
  • Antazoline Sulfate

    Product Antazoline Sulfate

    Fields of Application: Conjunctivitis. Antazoline Sulsphate is an ethylenediamine derivative with antihistaminic properties and is used in conjunction with a vasoconstrictor for ocular allergies.
  • Carbidopa

    Product Carbidopa

    Fields of Application: Parkinson's disease. Carbidopa, an aromatic L-amino acid decarboxylase inhibitor, which does not cross the blood-brain barrier, is routinely administered in combination with levodopa to patients with Parkinson’s disease to reduce the peripheral decarboxylation of levodopa to dopamine.
  • Etomidate

    Product Etomidate

    Fields of Application: Anesthesia. Etomidate is a rapid, short acting intravenous anesthetic agent with no analgesic properties and a relative lack of significant hemodynamic and respiratory effects.